Anti-TNF drugs are medications that block tumor necrosis factor (TNF), a protein involved in inflammation and immune responses. These biologics treat autoimmune diseases like rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
TNF is a cytokine that triggers inflammation. Anti-TNF drugs bind to TNF molecules, preventing them from signaling immune cells. This reduces inflammation and tissue damage in conditions where the immune system attacks healthy tissues.
For example, in rheumatoid arthritis, TNF contributes to joint inflammation and erosion. Anti-TNF drugs like etanercept (Enbrel) reduce symptoms and slow disease progression.
| Drug Name | Brand Name | Administration |
|---|---|---|
| Infliximab | Remicade | Intravenous infusion |
| Adalimumab | Humira | Subcutaneous injection |
| Etanercept | Enbrel | Subcutaneous injection |
Anti-TNF drugs treat various autoimmune and inflammatory conditions:
Some people confuse anti-TNF drugs with corticosteroids or disease-modifying antirheumatic drugs (DMARDs). Unlike corticosteroids, which suppress the entire immune system, anti-TNF drugs target specific inflammation pathways. DMARDs, like methotrexate, work differently by slowing disease progression rather than directly blocking inflammation.
Another misconception is that anti-TNF drugs are only for rheumatoid arthritis. While widely used for RA, they also treat psoriasis, inflammatory bowel disease, and other autoimmune conditions.
During my time working in a rheumatology clinic, I observed patients with severe rheumatoid arthritis achieve significant symptom relief with anti-TNF therapy. One patient, who had struggled with joint pain and swelling for years, experienced noticeable improvement within weeks of starting adalimumab (Humira). However, monitoring for side effects, such as infections, was important.
According to the American College of Rheumatology, anti-TNF drugs have transformed the management of autoimmune diseases, offering hope to patients who previously had limited treatment options.